An Effort to Detect and Treat Alzheimer’s at Its Earliest Stages

One of the challenges in treating the neurodegenerative condition Alzheimer’s disease is intervening early enough in the course of illness to provide meaningful benefit. AltPep is developing therapeutics with companion diagnostics that target toxic α-sheet–containing oligomers, which are thought to form very early in the disease and act as molecular triggers of downstream amyloid pathology. These structures are believed to represent some of the earliest detectable stages of Alzheimer’s and to promote the formation of amyloid plaques, a hallmark feature of the condition.​ We spoke with Valerie Daggett, founder and CEO of AltPep, about the relationship between α-sheet oligomers and the onset of Alzheimer’s disease, how the company’s synthetic peptides are designed to bind and neutralize these pathogenic agents, and the potential for this platform to be extended to a broader set of amyloid diseases.

You can listen to An Effort to Detect and Treat Alzheimer’s at Its Earliest Stages online on Radio and Podcast. Open the player on this page to stream the available audio.

An Effort to Detect and Treat Alzheimer’s at Its Earliest Stages is an episode from The Bio Report by Levine Media Group.

This episode is 29:20 long.

This episode was published on Jan 7, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from The Bio Report when more episodes are available from the podcast feed.